Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JSPR Jasper Therapeutics	$5.59 -0.7%	$4.91	$3.13 ▼ $26.05	$84.06M	2.72	301,487 shs	20,840 shs
MIRA MIRA Pharmaceuticals	$1.24 -1.2%	$1.16	$0.51 ▼ $5.01	$20.90M	1.96	823,657 shs	17,885 shs
PLRX Pliant Therapeutics	$1.36 -0.2%	$1.44	$1.10 ▼ $16.10	$83.30M	1.35	1.85 million shs	51,879 shs
ZURA Zura Bio	$1.18 -1.7%	$1.21	$0.97 ▼ $5.07	$80.68M	-0.12	434,472 shs	25,064 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JSPR Jasper Therapeutics	+0.90%	-5.22%	+14.20%	+7.85%	-77.50%
MIRA MIRA Pharmaceuticals	+3.31%	-3.10%	-13.79%	+6.84%	+69.38%
PLRX Pliant Therapeutics	-1.45%	-15.00%	-1.45%	-19.53%	-88.47%
ZURA Zura Bio	0.00%	-4.00%	+8.11%	-9.77%	-68.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JSPR Jasper Therapeutics	2.5956 of 5 stars	3.5	2.0	0.0	3.3	1.7	0.6
MIRA MIRA Pharmaceuticals	3.2115 of 5 stars	3.7	5.0	0.0	3.6	0.0	0.6
PLRX Pliant Therapeutics	4.3227 of 5 stars	3.0	4.0	4.7	3.4	1.7	0.6
ZURA Zura Bio	2.5014 of 5 stars	3.6	1.0	0.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JSPR Jasper Therapeutics	3.00	Buy	$62.22	1,012.90% Upside
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,033.60% Upside
PLRX Pliant Therapeutics	2.00	Hold	$13.31	881.02% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,114.69% Upside

Current Analyst Ratings Breakdown

Latest MIRA, JSPR, PLRX, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/18/2025	PLRX Pliant Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A
PLRX Pliant Therapeutics	$1.58M	52.72	N/A	N/A	$7.91 per share	0.17
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JSPR Jasper Therapeutics	-$64.46M	-$5.24	N/A	N/A	N/A	N/A	-67.64%	-58.53%	8/12/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$11.98M	-$0.51	N/A	N/A	N/A	N/A	-337.44%	-280.58%	8/12/2025 (Estimated)
PLRX Pliant Therapeutics	-$161.34M	-$3.61	N/A	N/A	N/A	N/A	-48.91%	-41.09%	8/6/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.70	N/A	N/A	N/A	N/A	-37.36%	-29.81%	8/12/2025 (Estimated)

Latest MIRA, JSPR, PLRX, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/28/2025	Q4 2024	MIRA MIRA Pharmaceuticals	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JSPR Jasper Therapeutics	N/A	7.61	7.61
MIRA MIRA Pharmaceuticals	N/A	6.11	6.11
PLRX Pliant Therapeutics	0.09	10.26	10.26
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JSPR Jasper Therapeutics	79.85%
MIRA MIRA Pharmaceuticals	35.16%
PLRX Pliant Therapeutics	97.30%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
JSPR Jasper Therapeutics	4.60%
MIRA MIRA Pharmaceuticals	6.65%
PLRX Pliant Therapeutics	8.00%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
MIRA MIRA Pharmaceuticals	2	16.92 million	15.46 million	Not Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.96 million	Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

MIRA, JSPR, PLRX, and ZURA Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23, 2025 | marketbeat.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA, JSPR, PLRX, and ZURA Company Descriptions

Jasper Therapeutics NASDAQ:JSPR

$5.59 -0.04 (-0.69%)

As of 10:01 AM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.24 -0.02 (-1.20%)

As of 09:58 AM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Pliant Therapeutics NASDAQ:PLRX

$1.36 0.00 (-0.22%)

As of 10:01 AM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zura Bio NASDAQ:ZURA

$1.18 -0.02 (-1.67%)

As of 09:55 AM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time